Surmodics Names Teri Sides as Chief Marketing Officer
EDEN PRAIRIE, Minn. November 01, 2018 –(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November 1, 2018.
“I am thrilled to welcome Teri to our internal team. Teri has been an important contributor to our business, product and clinical strategy since 2011, including being a founding member of our SurVeil, Avess and Sundance drug-coated balloon development programs,” said Gary Maharaj, President and Chief Executive Officer of Surmodics. “Her leadership and strategic marketing expertise will be critical to drive our efforts in developing differentiated products that deliver strong clinical and economic benefits while improving patient outcomes.”
Sides is an industry veteran, bringing over 27 years of medtech and healthcare experience. Prior to joining Surmodics, Teri served as Founder and Chief Executive Officer of Projectory, a consulting firm that provides strategic marketing services to med tech clients, ranging from start-ups to global businesses. Prior to Projectory, Sides was the Vice President of Marketing and Product Development for Arizant, Inc. Acting as the chief architect for product and market growth strategies, Teri led development of industry-leading products, including the world’s first patient warming gown. Sides holds an MBA from the University of Minnesota’s Carlson School of Management. She has more than eight patents granted and several pending.
“I look forward to joining the Surmodics team and leveraging our combined expertise to develop a meaningfully differentiated product pipeline,” said Sides. “Surmodics has demonstrated a commitment to innovation. Their talented development teams and key technology assets combined with the strength of their customer and clinical relationships enable the creation of highly innovative product solutions for vascular disease and in-vitro diagnostics.”
As CMO, Sides will be responsible for developing and driving strategic growth initiatives and will be a member of the senior leadership team reporting directly to Gary Maharaj, Chief Executive Officer.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2017, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
SOURCE: Surmodics, Inc.